Harbin sanlian pharmaceutical co., LTD. (hereinafter referred to as "Harbin sanlian") is a high-tech enterprise specialized in the research and development, production and sales of chemical pharmaceutical preparations.
The company was founded in 1996, 2001 freeze-dried powder needle, small volume injection, large volume injection one-time through the national GMP certification, the production capacity of the enterprise has been rapidly improved, the economic efficiency has been rapidly improved.
Since 2011, the company has been seeking prosperity and development on the basis of group operation, formally established the Harbin sanlian pharmaceutical research institute, and completed the shareholding reform in 2013. It was successfully listed on the shenzhen stock exchange on September 22, 2017.
The company adopts modern management concept and adheres to the principle of honest operation. For many years, the company has won the national "AAA credit enterprise in enterprise credit evaluation" and the 2016 top 100 in China's comprehensive drug r&d strength.
Future, the joint will continue to uphold the tenet of "triple, serve for you", to "the good if water, thick, saving their feelings, empty one and static style of cooperation to share the character of the" corporate culture to support this one characteristic, born within type growth and denotative expansion integration of industry resources, consolidate and upgrade manufacturing platform, to the listed as an opportunity to realize the industrial chain integration and the leapfrog development of the company, strive to build the main highlight, leading scale, first-class pharmaceutical enterprises with core competitiveness, to create the sanlian built in one hundred.
